Price T Rowe Associates Inc Xeris Biopharma Holdings, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 125,635 shares of XERS stock, worth $267,602. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125,635
Previous 115,003
9.24%
Holding current value
$267,602
Previous $271,000
2.58%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding XERS
# of Institutions
143Shares Held
57.3MCall Options Held
87.6KPut Options Held
80.4K-
Black Rock Inc. New York, NY9.96MShares$21.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.61MShares$16.2 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$10.9 Million69.8% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.17MShares$8.87 Million1.51% of portfolio
-
State Street Corp Boston, MA3.22MShares$6.85 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $290M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...